| Date | Title | Description |
| 15.05.2025 | A New Dawn for COPD Treatment: Dupixent's Approval in Singapore | In a significant breakthrough for chronic obstructive pulmonary disease (COPD) patients, Singapore has approved Dupixent (dupilumab) as the first biologic treatment for this debilitating condition. This decision, announced on May 14, 2025, ... |
| 13.05.2025 | Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S. | Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.
Tue, May 13, 2025 08:00 CET Report this content
Lund, Sweden, 13 May 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced that Maria ... |
| 23.04.2024 | Seamless Therapeutics Announces New CEO and Board Chairman to Support US Expansion of Programmable Recombinase Gene Editing Technology Platform | DRESDEN, Germany & LEXINGTON, Mass.--(BUSINESS WIRE)-- Seamless Therapeutics today announced the appointments of Albert Seymour, Ph.D., as its new President and Chief Executive Officer and Adam Rosenberg as Independent Chairman of the c... |
| 19.04.2024 | Notice of Annual General Meeting in BioArctic AB (publ) | Notice of Annual General Meeting in BioArctic AB (publ)
Fri, Apr 19, 2024 08:00 CET Report this content
The board of directors of BioArctic AB has resolved to convene an Annual General Meeting of shareholders to be held on Wednesday on 22 M... |
| 16.04.2024 | The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB | The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
Tue, Apr 16, 2024 15:00 CET Report this content
Stockholm April 16, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) her... |
| 12.03.2024 | ADHD medication linked to reduced mortality | ADHD medication linked to reduced mortality
Tue, Mar 12, 2024 17:00 CET Report this content
Researchers from Karolinska Institutet have shown a link between use of medication for ADHD and a reduced risk of premature death. The risk of death... |
| 06.03.2024 | Short Bowel Syndrome (SBS) Market Projected to Surge to $5.7 Billion Globally by 2030, with High CAGR in GLP-2 and Growth Hormone Segments | - |
| 27.09.2019 | How To Spot A Synthetic Biology Unicorn | Biotech is projected to reach $775 billion by 2024, but dozens of companies in the field of ... [+] synthetic biology are creating magical tools to go beyond that. Look here for the next unicorn. Jelena Trmčić for SynBioBeta |
| 23.08.2018 | Shire wins a blockbuster OK for pipeline star lanadelumab, boosting Takeda’s $62B takeover deal | The FDA wasted no time in stamping their quick approval on Shire’s marketing application for lanadelumab — one of the year’s top likely blockbusters in the industry pipeline. And that’s a critical endorsement for Takeda, w... |
| 26.05.2017 | BioCryst gets a big boost from its latest HAE data, but it still faces a dangerous high wire act and giant rivals | Jon Stonehouse
A little more than a year ago, shares of Research Triangle Park, NC-based BioCryst $BCRX were crushed by a failed Phase II trial for their lead drug for hereditary angioedema, or HAE. Setbacks like that are not new... |
| 19.04.2017 | Figure 1, a knowledge-sharing app for doctors, launches sponsored content | Since its launch in 2013, Figure 1, a photo- and knowledge-sharing app for medical professionals, has focused on “traction” that is winning over new users and keeping them around. The app now boasts registered users in 190 countries, with t... |
| 03.08.2015 | Morning Read: Shire gets late stage eye treatment with $300M deal, FDA warns Hospira’s Symbiq infusion system vulnerable to cyberattack | Concerns over hacking medical devices have resurfaced. This time the FDA has issued a safety alert that Humira’s Symbiq infusion system is vulnerable to cyberattack. The Department of Homeland Security first called attention to the pump, wh... |
| 23.07.2015 | Startups: Shire on the lookout for rare disease acquisitions | Irish pharma giant Shire is seeking out new acquisitions, despite the fact that valuations are swelling among biopharma upstarts, CEO Flemming Ornskov said.
“There are lots of exciting opportunities out there,” Ornskov said in a recent earn... |
| 17.08.2014 | Rady: From zero to 70 startups in 10 years | Ciara Kennedy was a program manager at biotechnology firm Biogen Idec in 2003 when she decided to advance her career by learning the business of science.
She built her business school wish list and when she began looking at her options, she... |
| 30.06.2014 | Bid target Shire gets $416m tax windfall boost | |
| 31.03.2014 | More research hospitals’ tech transfer offices are now business development offices, too | “It’s less of a traditional tech transfer approach, where you start with intellectual property that’s developed and you hopefully wait for someone to open the door and say that they want to license it,” said Nandan Padukone, vice president ... |
| 20.01.2014 | Shire ditches troubled Dermagraft skin substitute | Regenerative therapies maker Shire (NSDQ:SHPGY) announced that it sold its troubled Dermagraft business to Organogenesis in a deal worth up to $300 million in sales-based milestone payments.
Shire plans to record a $650 million loss on its ... |
| 11.11.2013 | Shire expands with $4.2bn acquisition of rare disease specialist ViroPhama | |
| 06.05.2013 | NeuroPhage Pharmaceuticals Raises $6.4M in Equity Financing | NeuroPhage Pharmaceuticals, Inc., a Cambridge, MA-based developer of therapies for neurodegenerative diseases, raised $6.4m in equity financing.
The round was led by Merieux Developpement, with participation from all current investors inclu... |
| 09.04.2013 | Rare disease survey: Physician-patient networks could cut down diagnosis time (infographic) | Among the reasons why it takes so long to diagnose a rare disease are, not surprisingly, they occur so infrequently that a lot of physicians lack experience identifying them and don’t recognize the symptoms. That means patients have to have... |
| 17.12.2012 | Naurex Raises $38M in Series B Financing | Naurex Inc., an Evanston, Illinois-based clinical-stage company focused on psychiatry and neurology, has raised $38m in Series B financing.
The round was led by new investor Baxter Ventures, with participation from new investor Savitr Capit... |
| 03.12.2012 | ArmaGen Technologies Raises $17M in Series A Funding | ArmaGen Technologies, a Santa Monica, CA-based developer of brain-penetrating recombinant protein therapeutics, has raised $17m in Series A funding.
The round was led by Boehringer Ingelheim Venture Fund, with participation from Shire plc, ... |
| 27.07.2012 | Fundraising: Gene therapy firm targeting sickle cell anemia raises $60M | Product: Gene therapy to target sickle cell anemia, beta-thalassemia and childhood cerebral adrenoleukodystrophy
Money raised: $60 million in series D; at least $76 million in previous rounds based on press releases and U.S. Securities and ... |
| 05.07.2012 | Pitches unplugged: Startup developing iPad app to determine real reasons people don’t take their meds (video) | But the company’s primary interest is advancing ownership of a diabetes model for which it plans to partner with a payer and is looking to raise $1 million to develop what will be an iPad diagnostic tool to identify noncompliance with treat... |
| 12.04.2012 | Shire’s asset acquisition to boost Regenerative Medicine Division | Vascugel is designed to alleviate complications that can be caused by establishing an arteriovenous (AV) access site using an AV graft. Using it on the outside of the vessel at the AV access site during surgery can help the blood vessel rec... |
| 28.03.2012 | Promethera Biosciences Raises €23.6M in Series B Funding | Promethera Biosciences, a Mont-Saint-Guibert, Belgium-based cell therapy company operating in the field of liver diseases, has raised €23.6m (approximately $31.4m) in Series B funding.
The company secured a capital increase of €17m and a lo... |
| 06.03.2012 | Diabetic foot ulcer treatment gets green light for phase 3 trials | The Princeton, New Jersey-based company, citing data from Susquehanna Research, said diabetic foot ulcers affect 900,000 people annually in the United States. The company estimates the value of the diabetic foot ulcer treatment market at $3... |
| 08.02.2012 | Success or withdrawal hang in balance for Shire blood pressure drug | Although the Irish pharmaceutical company, which has U.S. headquarters in the Philadelphia area, no longer manufactures the drug, it agreed to do the additional tests because it holds the new drug application for ProAmatine and did not want... |
| 07.02.2012 | Shire drug to manage ADHD symptoms in adults gets FDA approval | The Irish company with U.S. headquarters in Philadelphia, Pennsylvania, has sought to develop other ADHD treatments since losing exclusivity for Adderall to generic rivals in 2009. According to Morningstar analyst Karen Andersen, in 2008, a... |
| 16.12.2011 | Atlas Venture Partners with Shire to Invest in Companies Developing Rare Disease Therapeutics | Atlas Venture, a Cambridge, Mass.-based venture capital firm, has signed a multi-year partnership with Shire Human Genetic Therapies, a Dublin, Ireland-based, publicly traded, biopharmaceutical company, to explore investment opportunities i... |
| 05.12.2011 | Shire agrees to more clinical trials for blood pressure drug, but threat of FDA action lingers | Shire had resisted repeated requests for additional testing, arguing it had satisfied the testing requirements in 2005, but the FDA said it has not verified the clinical benefits of the drug. A letter sent to Shire in May 2001 said the comp... |
| 17.11.2011 | Chelsea’s Northera for Parkinson’s patients gets FDA priority review | Northera was developed by Japanese pharmaceutical company Dainippon Sumitomo Pharma. The company’s product, Droxidopa, was approved by Japan’s regulators in 1989 for treating frozen gait and dizziness on standing associated with Parkinson’s... |
| 02.11.2011 | Lessons from a $750M exit: Advanced BioHealing VP discusses sale to Shire | Tozer said that discussions with private equity firms came close to a deal. But in the second half of 2010, management decided to pursue an IPO. The offering would have valued the company at more than $600 million. But on the morning of May... |
| 25.08.2011 | Shire ditches Dermagraft for leg ulcers, just three months after dropping $750M on Advanced BioHealing | Shire plc (NSDQ:SHPGY) became the latest firm to abandon its pursuit of a leg ulcer indication for the Dermagraft artificial skin patch, after a clinical trial failed to pan out.
The Irish biopharmaceutical firm, which acquired the product ... |
| 01.03.2011 | NeuroPhage Pharmaceuticals Raises $12.4M in Series B Financing | NeuroPhage Pharmaceuticals, Inc., a Cambridge, MA-based biotechnology company developing a protein disaggregation platform for treatment of neurodegenerative diseases, has secured $12.4m in Series B financing.
The round, which was led by Me... |
| 02.02.2011 | Blood pressure drug misses in phase III; Chelsea aims for new target | Promoted
Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently during uncertain times.
SAP
Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R... |
| 27.08.2010 | Shire Announces European Approval of VPRIV® (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease | Cambridge, MA, US – August, 27th 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that the European Commission has granted marketing authorisation for VPRIV® (velaglucerase alfa), a... |
| 05.10.2007 | Life sciences briefing: Friday, Oct. 5, 2007 | Featured companies: Gilde Healthcare Partners, Konanda Pharma Partners, Healthvision, OrbiMed, Quovadx, Serentis, Surface, Visiopharm
Danish microscopy company Visiopharm gets funding — Copenhagen’s Visiopharm, a developer of image-analysis... |
| 18.09.2007 | Life sciences briefing: Tuesday, Sept. 18, 2007 | Featured companies: BioMicro Systems, Diasome Pharmaceuticals, FitLinxx, FitSense, Novartis, Radius Health
[NOTE: This is a catchup briefing, posted on 9/29/07. I’ve adjusted the item’s timestamp to keep the briefings in chronological order... |
| - | Shire’s asset acquisition to boost Regenerative Medicine Division | Shire (NASDAQ:SHPGY) has acquired the assets of a therapeutics firm, including a vascular surgery technology undergoing phase 2 clinical trials in a move that stands to bolster its regenerative medicine division.
As part of the agreement, S... |
| - | More research hospitals’ tech transfer offices are now business development offices, too | In the same way that funding for early-stage innovations is changing, so is how those innovations are translated from the bench to the bedside.
“Our office, which was formerly a traditional tech transfer office, has very much become a busin... |
| - | Morning Read: Shire gets late stage eye treatment with $300M deal, FDA warns Hospira’s Symbiq infusion system vulnerable to cyberattack | TOP STORIES
Shire has acquired Foresight Biotherapeutics in a $300 million deal. The purchase gives Shire access to a conjunctivitis treatment in late stage development. Dr. Flemming Ornskov, Shire CEO, said:
“Ophthalmics is a highly-attrac... |
| - | Diabetic foot ulcer treatment gets green light for phase 3 trials | U.S. regulators have agreed to phase 3 clinical trials for an advanced wound care device and drug developer’s treatment for diabetic foot ulcers following positive data from its phase 2 clinical trial.
Derma Science‘s (NASDAQ:DSCI) topical ... |
| - | Blood pressure drug misses in phase III; Chelsea aims for new target | Chelsea Therapeutics is shifting gears with a drug candidate intended for Parkinson’s disease patients, now choosing to focus on a new target after the compound missed its primary goal in late stage clinical trials.
Charlotte, North Carolin... |
| - | Chelsea’s Northera for Parkinson’s patients gets FDA priority review | Chelsea Therapeutics‘ (NASDAQ:CHTP) drug candidate for dizziness and fainting in Parkinson’s disease patients has been accepted for priority review by the U.S. Food and Drug Administration.
Priority review is reserved for drugs that either ... |
| - | Fundraising: Gene therapy firm targeting sickle cell anemia raises $60M | Company name: bluebird bio.
Industry: Biotechnology.
Location: Cambridge, Massachusetts.
Product: Gene therapy to target sickle cell anemia, beta-thalassemia and childhood cerebral adrenoleukodystrophy
Money raised: $60 million in series D;... |
| - | Lessons from a $750M exit: Advanced BioHealing VP discusses sale to Shire | Regenerative medicine company Advanced BioHealing is now part of Shire (NASDAQ:SHPGY), but before it was acquired last May, the Westport, Connecticut company was hours from pulling the trigger on an initial public stock offering.
ABH’s woun... |
| - | Shire agrees to more clinical trials for blood pressure drug, but threat of FDA action lingers | One year after Shire (NASDAQ:SHPGY) pulled its drug for low blood pressure, ProAmatine, from the market after reaching an impasse with the U.S. Food and Drug Administration, it has agreed to do the additional clinical tests the regulator wa... |
| - | Success or withdrawal hang in balance for Shire blood pressure drug | Shire (NASDAQ:SHPGY) has reached an agreement with U.S. regulators in the long-running saga over its low blood pressure drug, ProAmatine, that rests on the drug generating positive results in two clinical trials, or else face a withdrawal o... |
| - | Pitches unplugged: Startup developing iPad app to determine real reasons people don’t take their meds (video) | A medication adherence tool, an innovative lighting solution embedded in a cane and a device to measure brain activity for concussions were among the products pitched at a recent early stage venture event. Five companies made presentations,... |
| - | Shire drug to manage ADHD symptoms in adults gets FDA approval | Shire (NASDAQ: SHPGY) has secured approval from U.S. regulators for a drug to manage symptoms of Attention Deficit and Hyperactivity Disorder in adults.
Vyvanse has been approved as a maintenance treatment for ADHD. This new approval adds t... |
| - | Startups: Shire on the lookout for rare disease acquisitions | Irish pharma giant Shire is seeking out new acquisitions, despite the fact that valuations are swelling among biopharma upstarts, CEO Flemming Ornskov said.
“There are lots of exciting opportunities out there,” Ornskov said in a recent earn... |
| - | Rare disease survey: Physician-patient networks could cut down diagnosis time (infographic) | A new report is recommending developing more online networks as a way to shorten the more than seven year timeframe to diagnose a rare condition.
The report by drug developer Shire envisions these networks as connecting specialists with pat... |
